S106: UBTF-ATXN7L3 GENE FUSION DUE TO 17Q21.31 DELETION DEFINES NOVEL HIGH-RISK ALL SUBTYPE AMENABLE TO MRD-BASED TREATMENT INTENSIFICATION

• L. Bastian,
• A. Hartmann,
• T. Beder,
• S. Hänzelmann,
• J. Kässens,
• M. Bultmann,
• M. P. Höppner,
• S. Franzenburg,
• M. Wittig,
• A. Franke,
• I. Nagel,
• M. Spielmann,
• N. Reimer,
• H. Busch,
• S. Schwartz,
• B. Steffen,
• A. Viardot,
• K. Döhner,
• M. Kondakci,
• G. Wulf,
• K. Wendelin,
• A. Renzelmann,
• A. Kiani,
• H. Trautmann,
• M. Neumann,
• N. Gökbuget,
• M. Brüggemann,
• C. Baldus

Affiliations

L. Bastian

1 Department of Medicine II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Kiel

A. Hartmann

1 Department of Medicine II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Kiel

T. Beder

1 Department of Medicine II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Kiel

S. Hänzelmann

1 Department of Medicine II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Kiel

J. Kässens

1 Department of Medicine II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Kiel

M. Bultmann

1 Department of Medicine II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Kiel

M. P. Höppner

2 Institute for Clinical Molecular Biology, Kiel University, Kiel

S. Franzenburg

2 Institute for Clinical Molecular Biology, Kiel University, Kiel

M. Wittig

2 Institute for Clinical Molecular Biology, Kiel University, Kiel

A. Franke

2 Institute for Clinical Molecular Biology, Kiel University, Kiel

I. Nagel

3 Institute of Human Genetics, University Medical Center Schleswig-Holstein, Kiel and Lübeck, Kiel and Lübeck

M. Spielmann

3 Institute of Human Genetics, University Medical Center Schleswig-Holstein, Kiel and Lübeck, Kiel and Lübeck

N. Reimer

4 Medical Systems Biology Group and Institute for Cardiogenetics, University of Lübeck, Lübeck

H. Busch

4 Medical Systems Biology Group and Institute for Cardiogenetics, University of Lübeck, Lübeck

S. Schwartz

5 Department of Hematology, Oncology and Tumor Immunology (Campus Benjamin Franklin), Charité - Universitätsmedizin Berlin, Berlin

B. Steffen

6 Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt / Main

A. Viardot

7 Department of Internal Medicine III, University Hospital Ulm, Ulm

K. Döhner

7 Department of Internal Medicine III, University Hospital Ulm, Ulm

M. Kondakci

8 Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf

G. Wulf

9 Department of Hematology and Oncology, University Hospital Göttingen, Göttingen

K. Wendelin

10 Medical Department V, Hospital Nürnberg, Paracelsus Medizinische Privatuniversität, Nürnberg

A. Renzelmann

11 Medical Department Oncology and Hematology, University Medical Center Oldenburg, Oldenburg

A. Kiani

12 Department of Medicine IV, Hematology/Oncology, Klinikum Bayreuth, Bayreuth, Germany

H. Trautmann

1 Department of Medicine II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Kiel

M. Neumann

1 Department of Medicine II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Kiel

N. Gökbuget

6 Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt / Main

M. Brüggemann

1 Department of Medicine II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Kiel

C. Baldus

1 Department of Medicine II, Hematology and Oncology, University Medical Center Schleswig-Holstein, Kiel